HIV resistance to zidovudine: The role of pyrophosphorolysis

Drug Resistance Updates

Volumn 2, Issue 2, 1999, Pages 91-95

  Arion, Dominique ^a   Parniak, Michael A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PRIMER DNA; PYROPHOSPHATE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DNA SYNTHESIS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR MODEL; PHENOTYPE; PRIORITY JOURNAL; PYROLYSIS; REACTION ANALYSIS; SHORT SURVEY; VIRUS RESISTANCE;

EID: 0033014502     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0076     Document Type: Article

References (23)

1. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
2. Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA. 89:1992;1934-1938.
3. Larder B. A., Kellam P., Kemp S. D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-1 infected lymphocytes. AIDS. 5:1991;137-144.
4. Arts J. E., Quinones-Mateu M. E., Albright J. L. Mechanisms of clinical resistance of HIV-1 variants to zidovudine and the paradox of reverse transcriptase sensitivity. Drug Res Updates. 1:1998;21-28.
5. Wainberg M. A., Tremblay M. Results from the Canadian AZT Multicentre Study. Ann NY Acad Sci. 616:1991;346-355.
6. Lacey S. F., Reardon J. E., Furfine E. S. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'- deoxythymidine. J Biol Chem. 267:1992;15789-15794.
7. Carroll S. S., Geib J., Olsen D. B. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry. 33:1994;2113-2120.
8. Krebs R., Immendorfer U., Thrall S. H. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry. 36:1997;10292-10300.
9. Kerr S. G., Anderson K. S. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′- deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry. 36:1997;14064-14070.
10. Tantillo C., Ding J., Jacobo-Molina A. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J Mol Biol. 243:1994;369-387.
11. Perach M., Rubinek T., Hughes S. H. Analysis of HIV-2 RT mutants provides evidence that resistance of HIV-1 RT and HIV-2 RT to nucleoside analogs involves a repositioning of the template-primer. J Mol Biol. 268:1997;648-654.
12. Caliendo A. M., Savara A., An D. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol. 70:1996;2146-2153.
13. Canard B., Sarfati S. R., Richardson C. C. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′- monophosphate-terminated primer. J Biol Chem. 273:1998;14596-14604.
14. Arion D., Borkow G., Kaushik N. Phenotypic mechanism of HIV-1 resistance to 3′- azido, 3′-deoxythymidine (AZT): Increased DNA polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 37:1998;15908-15917.
15. Barshop B. A., Adamson D. T., Vellom D. C. Luminescent immobolized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5′-triphosphate sulfurylase. Anal Biochem. 197:1991;266-272.
16. Majumdar C., Abbotts J., Broder S. Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady state kinetics, processivity, and polynucleotide inhibition. J Biol Chem. 263:1988;15657-15665.
17. Hizi A., Tal R., Shaharabany M., Loya S. Catalytic properties of the reverse transcriptase of human immunodeficiency viruses type 1 and type 2. J Biol Chem. 266:1991;6230-6239.
18. Barnard J., Borkow G., Parniak M. A. The thiocarboxanilide UC781 is a tight-binding nonnucleoside inhibitor of HIV-1 reverse transcriptase. Biochemistry. 36:1997;7786-7792.
19. Borkow G., Arion D., Wainberg M. A., Parniak M. A. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 43:1999;259-263.
20. Larder B. A., Purifoy D. J. M., Powell K. L., Darby G. Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature. 327:1987;716-717.
21. Tachedjian G., Hooker D. J., Gurusinghe A. D. Characterization of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology. 212:1995;58-68.
22. Tachedjian G., Mellors J., Bazmi H. Zidovudine resistance is supressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol. 70:1996;7171-7181.
23. Rosowsky A., Fu H., Pai N. Synthesis and in vitro activity of long-chain 5′-O- [(alkoxycarbonyl)phosphinyl]-3′-azido-3′-deoxythymidines against wild type and AZT and foscarnet resistant strains of HIV-1. J Med Chem. 40:1997;2482-2490.